Stock Quote |
|
||||||||||||
0.14 (0.61%)
Corporate Profile
Abiomed (NASDAQ: ABMD) is a global technology leader focused on RECOVERING HEARTS AND SAVING LIVES.
Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.
More>>
More » Recent News
| Date | Title | |
|---|---|---|
| 05/17/13 |
DANVERS, Mass., May 17, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the UBS Global Health Care Conference on Wednesday, May 22, 2013 at 10:00 a.m. ET. The confere... |
|
| 05/08/13 |
DANVERS, Mass., May 8, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 at 9:2... |
|
| 05/03/13 |
DANVERS, Mass., May 3, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Bank of America Merrill Lynch 2013 Smid Cap Conference on Tuesday, May 7, 2013 at 3:50 p.m.... |
|
| 05/02/13 |
DANVERS, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2013 revenue of $43.7 million, up 17% compared to revenue of $37.3 million in the same period of fiscal 2012, and fourth quarter fiscal 2013 GAAP net income of $3.7 million ... |
|
| 05/01/13 |
DANVERS, Mass., May 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the publication of the PROTECT II Cost Effectiveness Study in the American Health & Drug Benefits (AHDB) journal, titled "A Value-Based Analysis of Hemodynamic Support Strategies for High-Risk H... |
|
Investor Relations
Investor Tools
|
|
Print Page |
|
E-mail Page |
|
RSS Feeds |
|
Snapshot |